LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Diatron Introduces New Aquila 5Dretic 5-Part Differential Hematology Analyzer

By LabMedica International staff writers
Posted on 20 Nov 2019
Image: Diatron Aquila 5Dretics (Photo courtesy of Diatron)
Image: Diatron Aquila 5Dretics (Photo courtesy of Diatron)
Diatron (Budapest, Hungary) introduced its new high throughput, 5-part differential hematology analyzer with continuous loading autoloader for the first time at the MEDICA 2019 Trade Fair held in Düsseldorf, Germany from 18-21st November. The MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals.

Diatron, a global provider of hematology and clinical chemistry analyzers, also showcased its P500 flagship clinical chemistry analyzer, and the Diatron KleeYa, an open, flexible CLIA platform, and demonstrated the Aquila 3-part diff hematology analyzer from its current hematology product portfolio.

The Diatron Aquila 5Dretics is the smallest and most compact cap piercing 5-part differential hematology analyzer with a maximum throughput of 80 tests per hour. It has a low reagent consumption (<30 ml), requires a small sample volume (40 ul) and has a continuous loading autoloader, making the walk away system convenient for all customers. It uses only two reagents as it is a fully optical system, resulting in low reagent consumption and making it more cost-effective. The Diatron Aquila 5Dretics requires little bench space (32 cm W x 30 cm D x 37 cm H without autoloader) and features a large touch screen, an intuitive user interface and a protected reagent pack system with unique connection

At the 2019 edition of MEDICA, Diatron also showcased its P500 flagship clinical chemistry analyzer. The P500 is an ergonomically designed, user-friendly system that offers a high level of automation and delivers assured result quality. The cost-effective, walkaway system is intended for medium throughput usage, providing results for 215 tests per hour on a typical sample mix. Also showcased at the event was Diatron KleeYa, a highly flexible, fast and sensitive random access chemiluminescence platform that provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment. The open platform system features a unique trigger cartridge technology that allows the use of both flash and glow detection technologies, along with unique stackable reaction cuvettes to eliminate system handling errors and reduce shipping and storage space.

Additionally, Diatron demonstrated the Aquila 3-part diff hematology analyzer which offers a throughput of 60 tests per hour, requires a sample size of only 10µl, and consumes less than 10ml of reagent per test. It is equipped with an onboard reagent pack sufficient for approximately 200 measurements and includes a touchscreen, intuitive user interface, optional backup battery pack, and extended connectivity options.

Related Links:
Diatron

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Sample Transportation System
Tempus1800 Necto

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more